ClinicalTrials.gg
CompletedNCT01687283Updated Oct 11, 2018Results posted

Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma

A Phase 3 interventional study of fluticasone propionate inhalation solution and budesonide suspension in Asthma, sponsored by GlaxoSmithKline. Completed at 25 sites in China. Open to participants aged 17 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-10-11.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
316
Allocation
Randomized
Ages
17 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 262 studies in Asthma by GlaxoSmithKline — 7 open to participants now, 12 under way, 7 of them phase 3. Asthma · GlaxoSmithKline.

Enrollment
72nd of 238
316 · median 93
Started
2012
with 22 others
Phase 3
61 of 262
6 open now
Registered
153rd of 262
by date

Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 72nd largest by enrollment of the 238 interventional ones that give a count, is one of 23 that started in 2012, is one of 61 in phase 3, and was the 153rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 262 studies in Asthma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 17 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in Asthma by GlaxoSmithKline, or all of them as a file.
02

Study summary

This is a multicentre, randomized, single-blind, active-controlled, parallel-group phase III local registration study for a treatment period of 12 weeks. This study aims to assess the effectiveness and safety of fluticasone propionate 1mg via nebulizer BID in treatment of Chinese adult and adolescent patients with severe persistent asthma for a treatment period of 12 weeks versus budesonide 2mg via nebulizer BID. The steady-state plasma pharmacokinetics of fluticasone propionate inhalation solution will also be assessed.

Read the detailed description

Male or female subjects between 17 to 70 (inclusive) years of age with severe persistent asthma meeting the inclusion criteria and having completed the screening period of 2 weeks will, in a proportion of 1:1, randomly receive fluticasone propionate 1mg via nebulizer BID or budesonide 2mg via nebulizer BID for a treatment period of 12 weeks. The clinic visit will be arranged at 2 weeks, 4 weeks, 8 weeks and 12 weeks during study treatment. If the subjects meet the criteria of pre-defined asthma control at treatment 4 weeks or 8 weeks, they will have one chance to be treated with the half dose of study drug. 2 weeks after completion of study treatment or after early withdrawal from study, the follow-up visit will be performed to assess the post-treatment adverse events. The primary endpoint is the mean change from baseline in morning peak expiratory flow (PEF) over the 12 week treatment period. Safety assessments include adverse events, vital signs, oral and oropharyngeal candidiasis, hematological, biochemical tests), 24-hour urinary cortisol and 12-lead ECG. The steady-state plasma pharmacokinetics of fluticasone propionate inhalation solution will also be assessed.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • fluticasone propionate inhalation solution
  • budesonide suspension for inhalation
  • efficacy
  • severe persistent asthma
  • pharmacokinetics
  • safety
04

Who can participate

Ages eligible
17 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chinese male or female outpatients aged >=17 years and \<=70 years
  • A female is eligible to enter and participate in this study if she is:

Non- (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchal, ), or Child-bearing potential, has a negative urinary pregnancy test at screening and agrees to take precautions (including abstinence) (referring to appendix 1: Highly Effective Methods For Avoidance Of Pregnancy In Women Of Childbearing Potential) which, in the opinion of the investigator are adequate to prevent pregnancy during the study.

  • A documented clinical history of asthma for a period of at least 12 weeks prior to Visit 1 based on the Guidance of Asthma Management and Prevention 2008 in China (refer to appendix 2).
  • Demonstrated >=12% and >=200mL reversibility of within 15-30minutes following inhalation of 200-400ug of salbutamol aerosol within 12 months prior to visit 1 or at the Screening Visit.
  • Subjects have pre-bronchodilator FEV1% predicted between >=40% and \<80% at visit 1.
  • Subjects on a stable dose at least 2 weeks with high dose ICS (eg. Fluticasone Propionate 500ug twice daily or other ICS with equivalence doses, refer to Appendix 3) or moderate dose ICS plus LABA (eg. Fluticasone Propionate/Salmoterol 250/50ug , twice daily; or Budesonide/Formoterol Fumarate in maintainance160/4.5ug, two inhalation, twice daily; or other product equivalence doses).
  • Subjects and/or their legally acceptable representative (if applicable) is willing to give to participate in the study, and having ability to comply with study procedures (including patients can use Nebulizer correctly, be able to understand and complete the diary cards and be able to record their PEF using a peak flow meter). The subjects and/or their legally acceptable representative (if applicable) will need to give additional informed consent to be eligible for blood pharmacokinetic samplings.

Exclusion criteria

Exclusion Criteria:

  • History of Life-threatening asthma: Defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest or hypoxic seizures.
  • Bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of visit 1 and led to a change in asthma management or, in the opinion of the investigator, is expected to affect the subject's asthma status or the subject's ability to participate in the study.
  • A subject must not have current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, , or other respiratory abnormalities other than asthma.
  • Subjects have any , uncontrolled condition or disease state that, in the opinion of the investigator, would put the safety of the patient at risk through study participation or would confound the interpretation of the efficacy results if the condition/disease exacerbated during the study.
  • Subjects will not b eligible for the run-in if he/she has clinical visual evidence of candidias at visit 1.
  • Current smoker or a smoking history of 10 pack years or more. A subject may not have used inhaled tobacco products (i.e., cigarettes, cigars or pipe tobacco) within the past 3 months.
  • Patients who are pregnant or lactating.
  • Patients having any known or suspected to or the of study drug, including Polysorbate 20, Sorbitan monolaurate, Monosodium phosphate dehydrate, Dibasic sodium phosphate anhydrous, Sodium Chloride and Water for Injection.
  • Patients who have evidence of alcohol abuse.
  • Patients who will have a pre-planned surgery operation in 6 months.
  • Liver function tests: (AST) / alanine aminotransferase (ALT) >= 2 × (ULN) or alkaline phosphatase (ALP) / >1.5 × ULN (isolated bilirubin >1.5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • Has >= 450 msec or >= 480 msec for patients with bundle branch block at the time of screening.
  • A subject will not be eligible for this study if he/she is an immediate family member of the participating Investigator, sub Investigator, study coordinator, or employee of the participating Investigator.
  • No subject is permitted to perform night shift work from Visit 1 until completion of the study treatment period.
  • Use of the following medications within the following time intervals prior to visit 1 or during the study: Medication / No use within the following time intervals prior to Screening (Visit 1) or at any time during the study Systemic or oral corticosteroids / 2 weeks Depot corticosteroids /12 weeks Anti-IgE (e.g. Xolair)/ 12 weeks Oral long-acting beta2-agonists (e.g. bambuterol) and inhaled long-acting beta2-agonists (e.g. salmeterol, formoterol) or combination products containing inhaled long-acting beta2-agonists (e.g. Seretide, Symbicort) / 12 hours (the stable dose of ICS/LABA combination within 2 weeks prior to Visit 1 could be continued during the run-in period) Theophyllines, slow-release bronchodilators, anticholinergics, ketotifen, nedocromil sodium, sodium cromoglycate, Anti-leukotrienes including suppressors of leukotriene production and antagonists / 1 day Inhaled short-acting beta2-agonist / 4 hours (salbutamol will be supplied for rescue during the study) Potent Cytochrome P450 3A4 inhibitors(e.g. ritonavir, ketoconazole, itraconzole) / 4 weeks Prescription or over the counter medication that would significantly affect the course of asthma, or interact with sympathomimetic amines, such as: anticonvulsants (barbiturates, hydantoins, carbamazepine); polycyclic antidepressants; beta-adrenergic blocking agents; phenothiazines and monoamine oxidase (MAO) inhibitors /1 day Chinese traditional medicines used for treatment of asthma and other allergic diseases / 1 week Any other drug / 30 days or within 5 half lives, whichever is longer
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
316 participants (actual)

Study arms

  • Experimental
    fluticasone propionate

    1 mg BID inhalation via nebulizer

    Drug: fluticasone propionate inhalation solution

  • Active comparator
    budesonide suspension

    2 mg BID inhalation via nebulizer

    Drug: budesonide suspension

Interventions

  • Drugfluticasone propionate inhalation solution

    1 mg BID inhalation for 12 weeks with one possible chance to change to 0.5 mg BID

  • 2 mg BID inhalation for 12 weeks with one possible chance to change to 1 mg BID

06

What researchers measure

Primary outcomes

  1. Change From Baseline (Day 1 of Treatment Period/Visit 2) in Morning Peak Expiratory Flow (AM PEF) Over 12 Weeks in Intent-to-treat Population

    The peak expiratory flow (PEF) is a person's maximum speed of expiration, A peak flow meter was issued to participants at Visit 1 to measure the morning PEF prior to study drug and rescue medication. The best of three attempts was recorded by the participants in the diary cards. Baseline value was the assessment at Visit 2. The raw and change from baseline in daily AM PEF averaged over the 12-week treatment period The mean value was considered missing if less than 4 days were recorded in the baseline week prior to randomization or if less than 4 days are recorded after randomization. Analysis was performed using analysis of covariance (ANCOVA) model. Abbreviations used in statistical analysis section: standard deviation (SD) and significance (sig)

    Time frame: Baseline (Visit 2) and up to Week 12

  2. Change From Baseline (Day 1 of Trt Period/Visit 2) in AM PEF Over 12 Weeks in Per Protocol Population

    The peak expiratory flow (PEF) is a person's maximum speed of expiration, A peak flow meter was issued to participants at Visit 1 to measure the morning PEF prior to study drug and rescue medication. The best of three attempts was recorded by the participants in the diary cards. Baseline value was the assessment at Visit 2. The raw and change from baseline in daily AM PEF averaged over the 12-week treatment period The mean value was considered missing if less than 4 days were recorded in the baseline week prior to randomization or if less than 4 days are recorded after randomization. Analysis was performed using analysis of covariance (ANCOVA) model.

    Time frame: Baseline (Visit 2) and up to Week 12

Secondary outcomes

  1. Mean Change of Evening PEF From Baseline Over 12 Weeks

    The peak expiratory flow (PEF) is a person's maximum speed of expiration, A peak flow meter was issued to participants at Visit 1 to measure the evening PEF prior to study drug and rescue medication. The best of three attempts was recorded by the participants in the diary cards. Baseline value was the assessment at Visit 2. The raw and change from baseline in daily PM PEF averaged over the 12-weeks treatment period.

    Time frame: Baseline (Visit 2) and up to Week 12

  2. Mean Change in Percentage of Symptom-free 24-hour Periods From Baseline Over 12 Weeks

    While calculating symptom-free 24-hour periods, a given 24-hour period was set to be "symptom free" only if the participant's responses to both the morning and evening assessments indicated no symptoms. The Baseline value was Visit 2 assessment and was derived from the last 7 days of the daily diary prior to the randomization. Change from Baseline was calculated as the difference between the value of the endpoint at the time point of interest and the baseline value. The value provided in outcome measure data is a consolidated value over Weeks 1 to 12.

    Time frame: Baseline (Visit 2) and over 12 Weeks

  3. Median Day-time and Night-time Symptom Scores Per Participant Over 12 Weeks

    Participants recorded day-time symptom score every day in the morning and evening at bedtime before taking any rescue or study medication and before PEF measurement, using 6 point scale on Diary Card indicating 0 = No symptoms during the day and 5 =Symptoms so severe that participant could not go to work or perform normal daily activities. Night time symptoms were scored while waking in the morning on a scale of 0 (no symptoms) to 4 (severe). The value provided in outcome measure data is a consolidated value over Weeks 1 to 12.

    Time frame: Over 12 Weeks

  4. Mean Change in Percentage of Rescue-free 24-hour Periods From Baseline Over 12 Weeks

    While calculating rescue-free 24-hour periods, the 24-hour period was only set to be "rescue free" if responses to both the morning and evening, assessments indicated no use of rescue medication. If there were symptoms in either the morning or the evening then that 24-hour period was set to as "not symptom free". Similarly, if there was rescue medication use in either the morning or the evening, then that 24-hour period was set to as "not rescue free". The Baseline value was Visit 2 assessment and was derived from the last 7 days of the daily diary prior to the randomization. The value provided in outcome measure data is a consolidated value over Weeks 1 to 12.

    Time frame: Baseline and over 12 weeks

  5. Median Number of Times Rescue Medication Use Over 12 Weeks

    Participants recorded the number of inhalations of rescue salbutamol inhalation aerosol used during the day and night. The baseline value was Visit 2 assessment and was derived from the last 7 days of the daily diary prior to the randomization. The analysis only included participants who had at least 2 days of non-missing numbers of times rescue medication (including zero) after randomization.

    Time frame: Up to week 12

  6. Change of Clinical Lung Function Measurement Forced Expiratory Volume in One Second (FEV1) From Baseline Over 12 Weeks

    FEV1 as a measure of lung function assessment was measured at Week 2, 4, 8 and 12. FEV1 measures were performed electronically by spirometry. The highest of three technically acceptable measurements was recorded. FEV1 was measured prior to study drug administration and any rescue salbutamol use. Baseline value was the assessment at Visit 2.Change from baseline was calculated as the value at the specific time point minus baseline value.

    Time frame: Baseline and at Week 2, 4, 8 and 12

  7. Steady-state Plasma Pharmacokinetics of Fluticasone Propionate Inhalation Solution- Time to Maximum Observed Plasma Concentration (Tmax)

    Tmax is defined as the time to maximum observed plasma concentration. Blood Pharmacokinetic (PK) samples were taken on Visit 3 (Day 14±2) pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose from participants. Blood sample for PK analysis, obtained within 72 hours of the last dose.

    Time frame: Pre-dose, 0.5 hour (h), 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose at Week 2

  8. Steady-state Plasma Pharmacokinetics of Fluticasone Propionate Inhalation Solution-maximum Observed Plasma Concentration (Cmax)

    Cmax was defined as maximum observed plasma concentration. Blood PK samples were taken on Visit 3 (Day 14±2) pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose from participants. Blood sample for PK analysis, obtained within 72 hours of last dose.

    Time frame: Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose at Week 2

  9. Steady-state Plasma Pharmacokinetics of Fluticasone Propionate Inhalation Solution-area Under the Plasma Concentration-time Curve for the Dose Interval [AUC (0-τ)]

    AUC (0-τ) was defined as the area under the plasma concentration-time curve for the dose interval. Blood PK samples were taken on Visit 3 (Day 14±2) pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose from participants. Blood sample for PK analysis, obtained within 72 hours of last dose.

    Time frame: Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose at Week 2

07

Results

Posted Jun 20, 2017

Participant flow

A total of 317 Chinese adults and adolescents aged \>= 17 years and \<= 70 years with severe persistent asthma were planned to be enrolled in study. This study was conducted from 27-September-2012 to 7-November-2013.

Participant flow — Overall Study
MilestoneFP 1 mg BIDBUD 2 mg BID
Started158157
Completed123130
Not completed3527
Withdrew: Adverse event114
Withdrew: Lack of efficacy31
Withdrew: Protocol violation13
Withdrew: Protocol defined stopping criteria810
Withdrew: Lost to follow-up11
Withdrew: Investigator discretion20
Withdrew: Withdrawal by subject98

Outcome measures

PrimaryChange From Baseline (Day 1 of Treatment Period/Visit 2) in Morning Peak Expiratory Flow (AM PEF) Over 12 Weeks in Intent-to-treat Population

The peak expiratory flow (PEF) is a person's maximum speed of expiration, A peak flow meter was issued to participants at Visit 1 to measure the morning PEF prior to study drug and rescue medication. The best of three attempts was recorded by the participants in the diary cards. Baseline value was the assessment at Visit 2. The raw and change from baseline in daily AM PEF averaged over the 12-week treatment period The mean value was considered missing if less than 4 days were recorded in the baseline week prior to randomization or if less than 4 days are recorded after randomization. Analysis was performed using analysis of covariance (ANCOVA) model. Abbreviations used in statistical analysis section: standard deviation (SD) and significance (sig)

Time frame:
Baseline (Visit 2) and up to Week 12
Reported as:
Least squares mean · Litres/Minute
Change From Baseline (Day 1 of Treatment Period/Visit 2) in Morning Peak Expiratory Flow (AM PEF) Over 12 Weeks in Intent-to-treat Population
Litres/MinuteFP 1 mg BIDBUD 2 mg BID
Change From Baseline (Day 1 of Treatment Period/Visit 2) in Morning Peak Expiratory Flow (AM PEF) Over 12 Weeks in Intent-to-treat Population12.71 ± 3.67714.51 ± 3.714
Statistical analysis
  • FP 1 mg BID vs BUD 2 mg BID · ANCOVA · p = 0.733 (Analysis performed using ANCOVA with covariates of baseline, center, sex, age and treatment) · Mean difference (net): -1.80 · 95% CI -12.19 to 8.59The analysis only included participants who had at least 4 days of non-missing AM PEF data in the baseline week prior to randomization and at least 4 days of non-missing AM PEF data after randomization.
PrimaryChange From Baseline (Day 1 of Trt Period/Visit 2) in AM PEF Over 12 Weeks in Per Protocol Population

The peak expiratory flow (PEF) is a person's maximum speed of expiration, A peak flow meter was issued to participants at Visit 1 to measure the morning PEF prior to study drug and rescue medication. The best of three attempts was recorded by the participants in the diary cards. Baseline value was the assessment at Visit 2. The raw and change from baseline in daily AM PEF averaged over the 12-week treatment period The mean value was considered missing if less than 4 days were recorded in the baseline week prior to randomization or if less than 4 days are recorded after randomization. Analysis was performed using analysis of covariance (ANCOVA) model.

Time frame:
Baseline (Visit 2) and up to Week 12
Reported as:
Least squares mean · Litres/Minute
Change From Baseline (Day 1 of Trt Period/Visit 2) in AM PEF Over 12 Weeks in Per Protocol Population
Litres/MinuteFP 1 mg BIDBUD 2 mg BID
Change From Baseline (Day 1 of Trt Period/Visit 2) in AM PEF Over 12 Weeks in Per Protocol Population13.50 ± 3.80615.78 ± 3.750
Statistical analysis
  • FP 1 mg BID vs BUD 2 mg BID · ANCOVA · p = 0.674 · Mean difference (net): -2.28 · 95% CI -12.95 to 8.38
SecondaryMean Change of Evening PEF From Baseline Over 12 Weeks

The peak expiratory flow (PEF) is a person's maximum speed of expiration, A peak flow meter was issued to participants at Visit 1 to measure the evening PEF prior to study drug and rescue medication. The best of three attempts was recorded by the participants in the diary cards. Baseline value was the assessment at Visit 2. The raw and change from baseline in daily PM PEF averaged over the 12-weeks treatment period.

Time frame:
Baseline (Visit 2) and up to Week 12
Reported as:
Least squares mean · Litres/Minute
Mean Change of Evening PEF From Baseline Over 12 Weeks
Litres/MinuteFP 1 mg BIDBUD 2 mg BID
Mean Change of Evening PEF From Baseline Over 12 Weeks12.39 ± 3.46915.16 ± 3.504
Statistical analysis
  • FP 1 mg BID vs BUD 2 mg BID · ANCOVA · p = 0.579 · Mean difference (net): -2.77 · 95% CI -12.57 to 7.04
SecondaryMean Change in Percentage of Symptom-free 24-hour Periods From Baseline Over 12 Weeks

While calculating symptom-free 24-hour periods, a given 24-hour period was set to be "symptom free" only if the participant's responses to both the morning and evening assessments indicated no symptoms. The Baseline value was Visit 2 assessment and was derived from the last 7 days of the daily diary prior to the randomization. Change from Baseline was calculated as the difference between the value of the endpoint at the time point of interest and the baseline value. The value provided in outcome measure data is a consolidated value over Weeks 1 to 12.

Time frame:
Baseline (Visit 2) and over 12 Weeks
Reported as:
Least squares mean · Percentage of symptom-free 24-hour
Mean Change in Percentage of Symptom-free 24-hour Periods From Baseline Over 12 Weeks
Percentage of symptom-free 24-hourFP 1 mg BIDBUD 2 mg BID
Mean Change in Percentage of Symptom-free 24-hour Periods From Baseline Over 12 Weeks21.77 ± 2.34021.15 ± 2.364
Statistical analysis
  • FP 1 mg BID vs BUD 2 mg BID · ANCOVA · p = 0.854 · Mean difference (net): 0.62 · 95% CI -6.00 to 7.24
SecondaryMedian Day-time and Night-time Symptom Scores Per Participant Over 12 Weeks

Participants recorded day-time symptom score every day in the morning and evening at bedtime before taking any rescue or study medication and before PEF measurement, using 6 point scale on Diary Card indicating 0 = No symptoms during the day and 5 =Symptoms so severe that participant could not go to work or perform normal daily activities. Night time symptoms were scored while waking in the morning on a scale of 0 (no symptoms) to 4 (severe). The value provided in outcome measure data is a consolidated value over Weeks 1 to 12.

Time frame:
Over 12 Weeks
Reported as:
Median · Score on Scale
Median Day-time and Night-time Symptom Scores Per Participant Over 12 Weeks
Score on ScaleFP 1 mg BIDBUD 2 mg BID
Median day-time symptom score1.0 (0 to 4)1.0 (0 to 4)
Median night-time symptom score1.0 (0 to 2)1.0 (0 to 3)
Statistical analysis
  • FP 1 mg BID vs BUD 2 mg BID · Wilcoxon rank sum test · p = 0.123
  • FP 1 mg BID vs BUD 2 mg BID · Wilcoxon rank sum test. · p = 0.949
SecondaryMean Change in Percentage of Rescue-free 24-hour Periods From Baseline Over 12 Weeks

While calculating rescue-free 24-hour periods, the 24-hour period was only set to be "rescue free" if responses to both the morning and evening, assessments indicated no use of rescue medication. If there were symptoms in either the morning or the evening then that 24-hour period was set to as "not symptom free". Similarly, if there was rescue medication use in either the morning or the evening, then that 24-hour period was set to as "not rescue free". The Baseline value was Visit 2 assessment and was derived from the last 7 days of the daily diary prior to the randomization. The value provided in outcome measure data is a consolidated value over Weeks 1 to 12.

Time frame:
Baseline and over 12 weeks
Reported as:
Least squares mean · Percentage of rescue -free 24-hours
Mean Change in Percentage of Rescue-free 24-hour Periods From Baseline Over 12 Weeks
Percentage of rescue -free 24-hoursFP 1 mg BIDBUD 2 mg BID
Mean Change in Percentage of Rescue-free 24-hour Periods From Baseline Over 12 Weeks19.27 ± 2.59524.01 ± 2.612
Statistical analysis
  • FP 1 mg BID vs BUD 2 mg BID · ANCOVA · p = 0.204 · Mean difference (net): -4.74 · 95% CI -12.07 to 2.59
SecondaryMedian Number of Times Rescue Medication Use Over 12 Weeks

Participants recorded the number of inhalations of rescue salbutamol inhalation aerosol used during the day and night. The baseline value was Visit 2 assessment and was derived from the last 7 days of the daily diary prior to the randomization. The analysis only included participants who had at least 2 days of non-missing numbers of times rescue medication (including zero) after randomization.

Time frame:
Up to week 12
Reported as:
Median · Number of Inhalations
Median Number of Times Rescue Medication Use Over 12 Weeks
Number of InhalationsFP 1 mg BIDBUD 2 mg BID
Median Number of Times Rescue Medication Use Over 12 Weeks0.0 (0 to 7)0.0 (0 to 4)
Statistical analysis
  • FP 1 mg BID vs BUD 2 mg BID · Wilcoxon Rank sum · p = 0.170
SecondaryChange of Clinical Lung Function Measurement Forced Expiratory Volume in One Second (FEV1) From Baseline Over 12 Weeks

FEV1 as a measure of lung function assessment was measured at Week 2, 4, 8 and 12. FEV1 measures were performed electronically by spirometry. The highest of three technically acceptable measurements was recorded. FEV1 was measured prior to study drug administration and any rescue salbutamol use. Baseline value was the assessment at Visit 2.Change from baseline was calculated as the value at the specific time point minus baseline value.

Time frame:
Baseline and at Week 2, 4, 8 and 12
Reported as:
Least squares mean · Litres
Change of Clinical Lung Function Measurement Forced Expiratory Volume in One Second (FEV1) From Baseline Over 12 Weeks
LitresFP 1 mg BIDBUD 2 mg BID
Week 20.122 ± 0.02830.161 ± 0.0281
Week 40.187 ± 0.03330.195 ± 0.0328
Week 80.175 ± 0.03140.201 ± 0.0309
Week 120.217 ± 0.03420.200 ± 0.0336
Statistical analysis
  • FP 1 mg BID vs BUD 2 mg BID · ANCOVA · p = 0.337 (Repeated Measures analysis adjusted for baseline, centre, sex, age, visit, treatment, visit by treatment interaction and visit by baseline interaction) · Mean difference (net): -0.039 · 95% CI -0.118 to 0.041
  • FP 1 mg BID vs BUD 2 mg BID · ANCOVA · p = 0.866 (Repeated Measures analysis adjusted for baseline, center, sex, age, visit, treatment, visit by treatment interaction and visit by baseline interaction.) · Mean difference (net): -0.008 · 95% CI -0.101 to 0.085
  • FP 1 mg BID vs BUD 2 mg BID · ANCOVA · p = 0.566 (Repeated Measures analysis adjusted for baseline, center, sex, age, visit, treatment, visit by treatment interaction and visit by baseline interaction) · Mean difference (net): -0.025 · 95% CI -0.113 to 0.062
  • FP 1 mg BID vs BUD 2 mg BID · ANCOVA · p = 0.727 (Repeated Measures analysis adjusted for baseline, center, sex, age, visit, treatment, visit by treatment interaction and visit by baseline interaction.) · Mean difference (net): 0.017 · 95% CI -0.078 to 0.112
SecondarySteady-state Plasma Pharmacokinetics of Fluticasone Propionate Inhalation Solution- Time to Maximum Observed Plasma Concentration (Tmax)

Tmax is defined as the time to maximum observed plasma concentration. Blood Pharmacokinetic (PK) samples were taken on Visit 3 (Day 14±2) pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose from participants. Blood sample for PK analysis, obtained within 72 hours of the last dose.

Time frame:
Pre-dose, 0.5 hour (h), 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose at Week 2
Reported as:
Geometric mean · Hour
Steady-state Plasma Pharmacokinetics of Fluticasone Propionate Inhalation Solution- Time to Maximum Observed Plasma Concentration (Tmax)
HourFP 1 mg BID
Steady-state Plasma Pharmacokinetics of Fluticasone Propionate Inhalation Solution- Time to Maximum Observed Plasma Concentration (Tmax)0.905 ± 59.9
SecondarySteady-state Plasma Pharmacokinetics of Fluticasone Propionate Inhalation Solution-maximum Observed Plasma Concentration (Cmax)

Cmax was defined as maximum observed plasma concentration. Blood PK samples were taken on Visit 3 (Day 14±2) pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose from participants. Blood sample for PK analysis, obtained within 72 hours of last dose.

Time frame:
Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose at Week 2
Reported as:
Geometric mean · picogram per milliliter (pg/mL)
Steady-state Plasma Pharmacokinetics of Fluticasone Propionate Inhalation Solution-maximum Observed Plasma Concentration (Cmax)
picogram per milliliter (pg/mL)FP 1 mg BID
Steady-state Plasma Pharmacokinetics of Fluticasone Propionate Inhalation Solution-maximum Observed Plasma Concentration (Cmax)59.24 ± 115.0
SecondarySteady-state Plasma Pharmacokinetics of Fluticasone Propionate Inhalation Solution-area Under the Plasma Concentration-time Curve for the Dose Interval [AUC (0-τ)]

AUC (0-τ) was defined as the area under the plasma concentration-time curve for the dose interval. Blood PK samples were taken on Visit 3 (Day 14±2) pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose from participants. Blood sample for PK analysis, obtained within 72 hours of last dose.

Time frame:
Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h and 12h post dose at Week 2
Reported as:
Geometric mean · Picogram hours per milliliter (pg*h/mL)
Steady-state Plasma Pharmacokinetics of Fluticasone Propionate Inhalation Solution-area Under the Plasma Concentration-time Curve for the Dose Interval [AUC (0-τ)]
Picogram hours per milliliter (pg*h/mL)FP 1 mg BID
Steady-state Plasma Pharmacokinetics of Fluticasone Propionate Inhalation Solution-area Under the Plasma Concentration-time Curve for the Dose Interval [AUC (0-τ)]403.0958 ± 70.5

Adverse events

Collected over Up to Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FP 1 mg BID1/158 (0.6%)4/158 (2.5%)23/158 (14.6%)
BUD 2 mg BID0/157 (0%)2/157 (1.3%)15/157 (9.6%)
Most frequent serious events
Most frequent serious events
EventFP 1 mg BIDBUD 2 mg BID
AsthmaRespiratory, thoracic and mediastinal disorders2/1582/157
InfectionInfections and infestations1/1581/157
Lung infectionInfections and infestations0/1581/157
SpondylolisthesisMusculoskeletal and connective tissue disorders1/1580/157
Nephrotic syndromeRenal and urinary disorders1/1580/157
Most frequent other events
Most frequent other events
EventFP 1 mg BIDBUD 2 mg BID
NasopharyngitisInfections and infestations13/15810/157
Upper respiratory tract infectionInfections and infestations10/1585/157

Baseline characteristics

The analysis was performed on intent-to-treat population. This population comprised of all participants randomized to treatment and who received at least one dose of study medication. Only the participants present at the indicated time point were analyzed.

Age, Continuous
Age, Continuous(Years)FP 1 mg BIDBUD 2 mg BIDTotal
Mean51.7 ± 9.8451.1 ± 6.6551.4 ± 9.74
Sex: Female, Male
Sex: Female, Male(Participants)FP 1 mg BIDBUD 2 mg BIDTotal
Female7771148
Male8186167
Region of Enrollment
Region of Enrollment(Participants)FP 1 mg BIDBUD 2 mg BIDTotal
China158157315
08

Study locations

25 sites
  • GSK Investigational Site
    Guangzhou, Guangdong 510080, China
  • GSK Investigational Site
    Guangzhou, Guangdong 510180, China
  • GSK Investigational Site
    Zhanjiang, Guangdong 524001, China
  • GSK Investigational Site
    Changsha, Hunan 410004, China
  • GSK Investigational Site
    Changsha, Hunan 410011, China
  • GSK Investigational Site
    Xuzhou, Jiangsu 221006, China
  • GSK Investigational Site
    Nanchang, Jiangxi 330006, China
  • GSK Investigational Site
    Shenyang, Liaoning 110001, China
  • GSK Investigational Site
    Shenyang, Liaoning 110015, China
  • GSK Investigational Site
    Yinchuan, Ningxia 750004, China
  • GSK Investigational Site
    Jinan, Shandong 250012, China
  • GSK Investigational Site
    Jinan, Shandong 250013, China
  • GSK Investigational Site
    Qingdao, Shandong 266071, China
  • GSK Investigational Site
    Taiyuan, Shanxi, China
  • GSK Investigational Site
    Chengdu, Sichuan 610041, China
  • GSK Investigational Site
    Chengdu, Sichuan 610072, China
  • GSK Investigational Site
    Hangzhou, Zhejiang, China
  • GSK Investigational Site
    Beijing, 100029, China
  • GSK Investigational Site
    Beijing, 100088, China
  • GSK Investigational Site
    Chongqing, 400038, China
  • GSK Investigational Site
    Chongqing, China
  • GSK Investigational Site
    Hangzhou, 310016, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Shanghai, 200072, China
  • GSK Investigational Site
    Wuxi, 214023, China
09

References and documents

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2012 to primary completion in Nov 2013, 13 months.

Results were first posted in Jun 2017, 3 years 7 months after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 13 months is below that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2012
First posted
Sep 18, 2012
StartActual
Sep 27, 2012
Primary completionActual
Nov 7, 2013
CompletionActual
Nov 7, 2013
Results first posted
Jun 20, 2017
Last update
Oct 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01687283
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 18, 2012
Start date
Sep 27, 2012
Primary completion
Nov 7, 2013
Completion
Nov 7, 2013
Results posted
Jun 20, 2017
Last update
Oct 11, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion